IngredientsZeaxanthin is a naturally occurring pigment belonging to the xanthophyll subclass of carotenoids. It belongs to a group of pigments known as xanthophylls, or oxygenated carotenoids, and has no provitamin A activity. The full chemical name for zeaxanthin is 3,3′-dihydroxy-β,β-carotene, reflecting the exact placement of hydroxyl groups on the #3 and #3′ carbon atoms of the end rings. A synonym used in regulatory and scientific literature is 3R,3′R-beta,beta-carotene-3,3′-diol. Its molecular formula is C40H56O2, with a molecular weight of 566.88 Da.
This molecule was given the common name "zeaxanthin" because it was first identified as the pigment which gives corn its yellow color; the scientific name for corn is Zea mays. Zeaxanthin is a xanthophyll that results from the hydroxylation process of β-carotene, which in the fruit maturation process leads to a decrease in the levels of its precursor.
Despite sharing an identical molecular formula with lutein, these isomers are distinguished by a single positional difference in the conjugated double-bond system: lutein contains one β-ionone ring and one ε-ionone ring, whereas zeaxanthin possesses two β-ionone rings. Both have the same number of double bonds in the chain, but there is a difference in the position of one of these double bonds in the ring, and this position makes zeaxanthin a better antioxidant, as it has one more conjugated double bond than lutein.
In general, carotenoids are tetra-terpenoid molecules having a 40-carbon skeleton made up of 8 isoprene units. The macular carotenoids — dietary lutein and zeaxanthin, and their conversion isomer meso-zeaxanthin — are non-provitamin A carotenoids; that is, they cannot be converted into vitamin A.
The macular pigment carotenoids have hydroxyl (O-H) functional groups attached at the 3 and 3′ positions of terminal ionone rings, connected by a rigid 22-carbon isoprenoid backbone with nine conjugated double bonds. The presence of O-H groups and their total number of conjugated double bonds determine their polarity, solubility, light-absorbing, and antioxidant properties. The maximum absorption of zeaxanthin is around 450 nm. The peak absorption of the macular pigment at 460 nm corresponds with the "blue light hazard" wavelength of 450–500 nm.
While lutein occurs as a single stereoisomer, zeaxanthin occurs as a mixture of three stereoisomers: (3R,3′R)-zeaxanthin, (3R,3′S)-zeaxanthin (meso-zeaxanthin), and (3S,3′S)-zeaxanthin. In plant raw material, (3R,3′R)-zeaxanthin is the main form; in animal sources such as fish and shellfish, zeaxanthin exists in the (3R,3′S) and (3S,3′S) forms.
The presence of hydroxyl groups on two of the outermost carbon atoms makes xanthophylls such as zeaxanthin more water-soluble than other, very hydrophobic carotenoids. Synthetic zeaxanthin is greater than 96% pure and is equivalent to natural zeaxanthin from typical human food in all aspects, including the distribution of geometric isomers.
Carotenoids cannot be synthesized in vivo by vertebrates and invertebrates, and they must therefore be obtained from dietary consumption. Lutein and zeaxanthin are carotenoid pigments that impart yellow or orange color to various common foods such as cantaloupe, pasta, corn, carrots, orange/yellow peppers, fish, salmon, and eggs.
Green leafy vegetables such as kale, spinach, and broccoli are rich sources of lutein, while corn products are rich sources of zeaxanthin. Key sources of these carotenoids include kale, savoy cabbage, spinach, broccoli, peas, parsley, corn, and egg yolks. The recommended daily intake of zeaxanthin is approximately 2 mg; lutein intake in adults varies, with average intakes being 1–2 mg/day.
Zeaxanthin is commonly found in many fruits and vegetables, most notably Chinese wolfberries (goji berries) of the genus Lycium and the fruits of paprika plants of the genus Capsicum. The fruit pods of orange paprika (Capsicum annuum) exhibit hyperaccumulation of carotenoid pigment in the dried ripe fruit flesh, in which zeaxanthin is the dominant carotenoid.
In marigold (Tagetes erecta), there is approximately 2 g of xanthophylls per 100 g of fresh flowers, mainly lutein (accounting for more than 90%), with the remainder being zeaxanthin and a few other carotenoids. Among sources from other higher plants and algae, lutein generally accounts for a larger proportion relative to zeaxanthin, while zeaxanthin is higher than lutein in corn.
Microbial and microalgal sources are also documented. Flavobacterium sp. are well documented in zeaxanthin production. Cyanobacteria such as Paracoccus zeaxanthinifaciens and Phormidium laminosum have also been reported to produce zeaxanthin. Other microbial sources include Dunaliella sp., which produce zeaxanthin under stress and altered conditions.
Zeaxanthin is found in many plants, including green leafy and yellow-orange vegetables and fruits, such as carrots, corn, oranges, paprika, saffron, and wolfberries (goji).
Zeaxanthin is commercially available in several forms. One commonly available commercial extract is derived from flowers of a specialized variety of marigold (Tagetes erecta) bred to have higher levels of zeaxanthin relative to lutein and other carotenoids. In dietary supplement labeling documented by the NIH Dietary Supplement Label Database, common commercial preparations include free zeaxanthin, trans-zeaxanthin, 3R,3′R-zeaxanthin, and branded marigold flower extracts such as FloraGLO and Lutemax 2020.
The goji berry, a natural source of zeaxanthin dipalmitate, is eaten raw, consumed in juice form, or added to tea or wine; the fruit is also processed to make tinctures, powders, and tablets. In supplement formulations, zeaxanthin is typically encapsulated in softgels in oil suspension to improve its fat-soluble absorption. Because oral bioavailability of zeaxanthin is limited due to its hydrophobic nature, lipid-based delivery systems may enhance absorption. Due to poor intestinal absorption and stability, lutein and zeaxanthin in their natural form have low bioavailability after oral intake, leading to variable plasma concentrations.
The primary traditional context for zeaxanthin-containing botanical medicine is the goji berry (Lycium barbarum, known in Chinese as gou qi zi). Lycium barbarum berries — also named wolfberry or goji berry, family Solanaceae — have been used in the People's Republic of China and other Asian countries for more than 2,000 years as a traditional Chinese medicinal herb. Goji berry is a popular fruit consumed in China and used in Traditional Chinese Medicine. Its description and indications first appeared in The Divine Husbandman's Classic of Materia Medica (Shennong Ben Cao Jing). In TCM, goji berry treats kidney yin and liver blood deficiencies and their related symptoms such as dry eyes and blurred or decreased vision.
Lycium barbarum has been used for over 2,000 years in Traditional Chinese Medicine, with the first records dating back to the Tang Dynasty. Goji berry has been used as a medicine and functional food in Asia since ancient times; in traditional Chinese medicine, the beneficial action of goji berries was related to their ability to contribute to the regeneration and stimulation of the liver and kidneys, improve vision, and act as a tonic.
Lycium barbarum, commonly known as wolfberry, is a plant whose dried mature fruit is used in traditional Chinese medicine for its protective effects on the nervous system, immune-boosting properties, blood sugar control, and eye protection.
Lycium has also been used by European herbalists since ancient times and was traded from the Far East by the Romans. Pliny the Elder of Ancient Rome describes boxthorn (Lycium) as a medicinal plant used to treat sore eyes and inflammation. Zeaxanthin as an isolated compound was not identified in antiquity; its association with traditional preparations is exclusively via the whole plant and food sources that contain it.
It is important to note that none of these traditional uses were based on knowledge of zeaxanthin as a specific chemical entity. The yellow pigmentation of the fovea is the origin of the anatomical term macula lutea, or "yellow spot." The absorption spectra of the pigments from this region were recognized to be similar to those of xanthophylls, and subsequently they were chemically identified to be lutein, zeaxanthin, and meso-zeaxanthin. This chemical identification was a product of modern science, not traditional knowledge.
The human macula uniquely concentrates three carotenoids: lutein, zeaxanthin, and meso-zeaxanthin. Lutein and zeaxanthin must be obtained from dietary sources such as green leafy vegetables and orange and yellow fruits and vegetables, while meso-zeaxanthin is rarely found in the diet and is believed to be formed at the macula by metabolic transformations of ingested carotenoids.
The macular carotenoids responsible for macular pigment optical density (MPOD) are lutein, zeaxanthin, and meso-zeaxanthin at an approximate ratio of 2:1:1 in the retina. Lutein- and zeaxanthin-specific binding proteins — StARD3 and GSTP1, respectively — mediate the highly selective uptake of macular pigment into the retina.
In the context of the goji berry, zeaxanthin is found predominantly in esterified form. Goji berry (Lycium barbarum) has been widely used in traditional Chinese medicine, and the fruit is a major source of zeaxanthin dipalmitate (ZD), a xanthophyll carotenoid shown to benefit the liver.
The peak absorption of the macular pigment at 460 nm corresponds with the "blue light hazard" wavelength of 450–500 nm. Depending on its concentration, the macular pigment acts as a blue light filter that absorbs 40–90% of incident short-wavelength, high-energy visible blue light, protecting the retina from light-induced damage. Blue-light absorption can be considered an indirect antioxidant action because it prevents blue light from generating reactive oxygen species that can damage photoreceptor cells.
Recent clinical trials have determined that age- and diet-related loss of lutein and zeaxanthin enhances phototoxic damage to the human eye and that supplementation of these carotenoids has a protective effect against photoinduced damage to the lens and the retina. Two of the major mechanisms of protection offered by lutein and zeaxanthin against age-related blue light damage are the quenching of singlet oxygen and other reactive oxygen species, and the absorption of blue light.
Macular carotenoids are estimated to absorb 40% to 90% of incident blue light, depending on concentration; this absorption protects the retina from light-related damage and reduces light scatter. The highest density of macular carotenoids in the fovea is in the outer plexiform layer, a layer of neuronal synapses in the retina localized between rod and cone photoreceptors and their axons and other retinal neurons. This location is thought to be ideal to protect the outer retina (containing rod and cone photoreceptors) from photo-oxidative damage.
Zeaxanthin acts as a more potent antioxidant than lutein, protecting against oxidative stress in other tissues as well as the eyes.
In addition to their integral role in the prevention of blue light and UV-induced photo-oxidation of the retinal pigments, lutein and zeaxanthin also impart the ability to avoid chromatic aberration and increase the ability to discern visual stimuli based on wavelength, a phenomenon termed contrast sensitivity. Lutein and zeaxanthin cut out the blue light from the spectrum to minimize glare, luminance, and chromatic aberration, thus effectively increasing contrast sensitivity.
GSTP1, a pi-class glutathione S-transferase isoform, has been identified as a zeaxanthin- and meso-zeaxanthin-binding protein localized in the retina. The localization of GSTP1 in the macula as a zeaxanthin-binding protein suggests that GSTP1 also plays an important role in modulating antioxidant levels in the macula.
Some carotenoids, such as lutein and zeaxanthin, can cross the blood–brain barrier, reach the brain, and accumulate in the macular pigment of the retina. In fact, 66 to 77% of the total carotenoid content in human brain tissue is made up of lutein and zeaxanthin. There is growing interest in the neuroprotective benefits of lutein and zeaxanthin since they have been found in the hippocampus, cerebellum, frontal, occipital, and temporal cortices, and they also have potent antioxidant and anti-inflammatory capacities.
The presence of carotenoids (including zeaxanthin) and their isomers in human skin can protect against oxidation. Animal model research has further clarified a specific Nrf2-mediated pathway: zeaxanthin activated nuclear factor erythroid 2-related factor 2 (Nrf2) to approximately three times the level of the model group, significantly promoting the expression of various antioxidant enzymes and enhancing the total antioxidant capacity of skin tissue, subsequently reducing oxidative stress. Zeaxanthin also downregulated the expression of matrix metalloproteinases, reducing collagen degradation by 35% compared to the model group. This study was conducted in mice, and direct human clinical evidence for these specific mechanisms is limited.
AMD is the area of strongest clinical evidence for zeaxanthin. Observational studies have reported that increased dietary intake and higher serum levels of lutein and zeaxanthin are associated with lower risk of age-related macular degeneration (AMD), especially late AMD.
The landmark clinical trial is the Age-Related Eye Disease Study 2 (AREDS2). The primary purpose of AREDS2 was to evaluate the efficacy and safety of lutein plus zeaxanthin (L+Z) and/or ω-3 long-chain polyunsaturated fatty acid supplementation in reducing the risk of developing advanced AMD. The trial enrolled 4,203 participants at 82 clinical centers in the United States.
The primary AREDS2 finding was nuanced: the addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation does not statistically reduce the risk of progression to advanced AMD overall; however, lutein + zeaxanthin could serve as an appropriate substitute for beta-carotene due to a potential increased incidence of lung cancer with the latter.
Secondary analyses of AREDS2 provided more compelling data. In analyses restricted to eyes with bilateral large drusen at baseline, the direct comparison of lutein/zeaxanthin vs. beta-carotene showed hazard ratios of 0.76 (95% CI, 0.61–0.96; P = .02) for progression to late AMD, and 0.65 (95% CI, 0.49–0.85; P = .002) for neovascular AMD. The totality of evidence on beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than beta-carotene in the AREDS-type supplements.
Long-term follow-up data reinforced this conclusion. Results of a long-term epidemiologic follow-up study of the AREDS2 cohort suggest that lutein/zeaxanthin was an appropriate replacement for beta-carotene in AREDS2 supplements. Beta-carotene usage nearly doubled the risk of lung cancer, whereas there was no statistically significant increased risk with lutein/zeaxanthin. When compared with beta-carotene, lutein/zeaxanthin had a potential beneficial association with late AMD progression.
The AREDS2 study group found that individuals low in dietary lutein and zeaxanthin were about 25% less likely to develop advanced AMD compared to participants with similar dietary intake who did not take lutein and zeaxanthin.
The AREDS group also reported that dietary lutein/zeaxanthin intake was inversely associated with the incidence of neovascular AMD; the incidence was lower in the high-carotenoid intake group than in the low-carotenoid intake group.
Strength of evidence: The evidence in AMD is strong, supported by one of the largest and most rigorously conducted multicenter RCTs in nutritional ophthalmology, along with consistent epidemiological data. The benefit is most clearly established as a safer substitute for beta-carotene in the AREDS formulation, and in subgroups with low dietary intake at baseline.
A 2016 meta-analysis of 20 randomized controlled trials found that lutein, zeaxanthin, and meso-zeaxanthin supplementation improves MPOD in both healthy subjects and in AMD patients in a dose-response manner. These improvements were also positively associated with increases in serum lutein/zeaxanthin levels.
In a clinical trial in early AMD patients, patients were randomly assigned to receive 10 mg/day lutein, 20 mg/day lutein, 10 mg/day lutein plus 10 mg/day zeaxanthin, or placebo for 48 weeks. Macular pigment optical density increased significantly by a mean ± SE of 0.076 ± 0.022 density units in the 20-mg lutein group and 0.058 ± 0.027 density units in the lutein and zeaxanthin group during 48 weeks.
Study findings strongly support the regular use of lutein and zeaxanthin complex-5:1 supplementation to enhance MPOD levels; this supplementation not only improves macular pigment levels but also enhances visual acuity, contrast sensitivity, and sleep quality.
In a small randomized interventional trial in patients with macular telangiectasia type 2 (MacTel), eight MacTel patients were randomized to 10 mg or 20 mg of zeaxanthin per day, and were assessed at baseline and after 6, 12, 18, and 24 months, with measures including best-corrected visual acuity, contrast sensitivity, and serum carotenoid levels. Although the study showed no beneficial effect of zeaxanthin supplementation on objective measures in this specific disease, many of the subjects felt that they were seeing better.
Macular pigment, composed of lutein, zeaxanthin, and meso-zeaxanthin, has been shown to enhance visual function in normal subjects and is postulated to protect against AMD, likely through filtering blue light and its antioxidant properties. Several reports show that the macular pigment level is associated with macular function evaluated by visual acuity, contrast sensitivity, and multifocal electroretinogram.
Strength of evidence: Strong and consistent evidence from multiple RCTs and meta-analyses that supplementation increases MPOD. The relationship between MPOD increase and improved clinical visual outcomes (especially long-term protection) is supported but not universally confirmed across all patient populations.
Age-related cataracts are a leading cause of blindness. Antioxidants are of particular interest for their potential role in reducing oxidative damage leading to cataract formation. Lutein and zeaxanthin are the only carotenoids found within the human lens, although in significantly lower concentrations compared to the retina.
Data from AREDS2 also addressed cataracts: a significantly lower risk of progression to cataract surgery was found in those who were lutein + zeaxanthin supplemented compared to those who were not (HR = 0.68; 95% CI 0.48 to 0.96; p = 0.03).
Epidemiological studies indicate an inverse relationship between xanthophyll intake or status and both cataracts and age-related macular degeneration, suggesting these compounds may be protective.
Strength of evidence: Moderate. Epidemiological studies are consistently supportive, and one secondary analysis from AREDS2 showed a statistically significant reduction in risk of cataract surgery, but targeted RCTs with cataract outcomes as primary endpoints are limited.
Past studies have suggested that higher lutein and zeaxanthin levels in serum and in the central nervous system (as quantified by measuring MPOD) are related to improved cognitive function in older adults. Very few studies had, until recently, addressed the issue of xanthophylls and cognitive function in younger adults.
A 6-month randomized, double-blind, placebo-controlled trial assessed 90 volunteers aged 40–75 years who received either 10 mg of lutein and 2 mg of zeaxanthin once daily, or placebo, in a two-arm, parallel-group design. The results suggest that 6 months of supplementation with lutein and zeaxanthin may improve visual memory and learning in community-dwelling adults with self-reported cognitive complaints; however, it had no other effect on other computer-based measures of cognitive performance.
A meta-analysis of randomized intervention trials found that administration of lutein or lutein plus zeaxanthin may improve cognitive effects in older men and women. Women who received lutein 12 mg/day for 4 months improved verbal fluency scores. Men and women who received lutein 12 mg plus zeaxanthin 2 mg for 12 months improved domains of the CNS Vital Signs test battery, such as complex attention, cognitive flexibility, and composite memory.
Serum lutein and zeaxanthin were consistently significantly related to better cognition in both a whole population of octogenarians (n = 78) and centenarians (n = 220).
Strength of evidence: Preliminary to moderate. Several small-to-medium RCTs show improvements in specific cognitive domains, but overall the body of clinical evidence is heterogeneous in design, population, and outcomes measured. Larger, dedicated trials are needed.
Common C40 carotenoids, such as β-carotene, lycopene, astaxanthin, lutein, and zeaxanthin, demonstrate remarkable antioxidant activity, primarily attributed to their conjugated double bond structures. Many studies have demonstrated that both oral and topical administration of these C40 carotenoids can effectively alleviate skin photoaging.
In a clinical study by Palombo et al., oral, topical, and combined administration of lutein and zeaxanthin showed a significant improvement in the prevention of skin lipid peroxidation and improvement in free radical-related photoprotective activity compared with placebo group.
A significant amount of esterified xanthophylls are found in the human skin, implicating their roles in protection of the skin from harmful UV radiation.
Strength of evidence: Preliminary. Most mechanistic data come from animal models and in-vitro studies. Human clinical trials are small and few; the photoprotective evidence for zeaxanthin specifically is less robust than for beta-carotene, which has more dedicated human trial data.
Research has explored the specific esterified form found in goji berries, zeaxanthin dipalmitate (ZD), in the context of liver health. Studies have shown the hepatoprotective, antifibrotic, antioxidant, anti-inflammatory, antiapoptotic, antitumor, and chemopreventive properties of ZD. These findings suggest that ZD-based drugs could hold promise for many liver disorders.
Strength of evidence: Largely preclinical (animal and cell-based studies). Human clinical trial data for zeaxanthin dipalmitate in liver disease are lacking or very limited. This area warrants further investigation before clinical conclusions can be drawn.
Zeaxanthin is available commercially as softgel capsules, tablets, powders, and in combination eye-health formulas typically combined with lutein, meso-zeaxanthin, vitamins C and E, and zinc. Dosages reported in published clinical trials vary by indication:
Zeaxanthin is Generally Recognized as Safe (GRAS) by the FDA for use in a wide range of food products, including baby and toddler foods, cereals, beverages, and dairy products. Kemin's review of published animal and human clinical studies concluded that no adverse effects from zeaxanthin or lutein have been reported, demonstrating that zeaxanthin is well tolerated by humans and does not raise safety concerns.
In vitro genotoxicity tests demonstrated that zeaxanthin was neither mutagenic nor clastogenic. In a 90-day oral toxicity study in Sprague-Dawley rats administered zeaxanthin by oral gavage once daily, no adverse effects were observed, and the NOAEL was reported to be 77 mg zeaxanthin/kg body weight/day, the highest dose tested.
There are no known safety signals for lutein and/or zeaxanthin within the typical dosing ranges. Large studies with follow-ups of 5 to 10 years have not identified long-term safety concerns.
The European Food Safety Authority (EFSA) concluded that synthetic zeaxanthin is safe at daily doses up to 53 mg.
The most commonly reported adverse effect is carotenodermia — a benign, harmless, and reversible yellow-orange discoloration of the skin that may occur with very high or prolonged intake, typically at doses exceeding 15–20 mg daily over months. This condition resolves upon reduction or cessation of intake. Very large doses of carotenoids such as lutein and zeaxanthin can cause carotenodermia — a yellow-orange skin discoloration that can look like jaundice, but the abnormal skin color can be removed with an alcohol swab, distinguishing it from true jaundice.
There is no known interaction between warfarin and zeaxanthin documented in the peer-reviewed literature. A PubMed search found no relevant studies when the keywords 'warfarin' and 'zeaxanthin' were combined. Zeaxanthin is a mild inhibitor of CYP3A4/5, one of the cytochrome P450 enzymes responsible for the 10-hydroxylation of the warfarin R-isomer, but at a level unlikely to cause a clinically significant interaction.
High-dose supplementation with one xanthophyll carotenoid can potentially affect serum levels of others, as they compete for absorption via shared lipid transport pathways. A meta-analysis of 20 RCTs found that the improvements in MPOD from supplementation were positively associated with increases in serum lutein/zeaxanthin levels, indicating that serum levels respond reliably to supplementation at tested doses; however, the competitive interaction with other fat-soluble micronutrients (particularly high-dose beta-carotene) has been noted in the AREDS2 context.
Human pharmacokinetic studies show that consuming lutein and zeaxanthin through diet or supplementation increases their levels in the blood, which enhances their deposition in the macula. However, due to poor intestinal absorption and stability, lutein and zeaxanthin in their natural form have low bioavailability after oral intake, leading to variable plasma concentrations. Co-ingestion with dietary fat is generally recommended to enhance absorption, consistent with the fat-soluble nature of all carotenoids.
Health conditions that Zeaxanthin may help support.
Zeaxanthin, a xanthophyll carotenoid, is a well-documented antioxidant that scavenges reactive oxygen species (ROS) and quenches lipid peroxidation, particularly in ocular and skin tissues. It activates the Nrf2/phase-II enzyme pathway, upregulating endogenous defenses including glutathione. Human and cell-based studies demonstrate it reduces markers of oxidative damage (MDA, protein carbonyls, DNA strand breaks) and protects retinal and lens cells from oxidant challenge. Clinical evidence is strongest in the context of ocular antioxidant defense, with supporting data from skin and systemic lipid peroxidation models.
Zeaxanthin is a xanthophyll carotenoid that co-occurs with lutein in greens and accumulates in the arterial wall, reducing LDL oxidation, inhibiting arterial macrophage foam cell formation, and reducing arterial oxidative stress. Like lutein, it is supported by mechanistic and observational evidence for arterial protection, though large isolated RCT data are lacking.
A double-blind, placebo-controlled supplementation study found that lutein, zeaxanthin, and meso-zeaxanthin together significantly decreased pro-inflammatory cytokines IL-1β and TNF-α and reduced serum oxidized LDL in human participants. Zeaxanthin's antioxidant structure enables it to quench reactive oxygen species and modulate inflammatory signaling pathways. Evidence is strongest for the combination of macular xanthophylls rather than zeaxanthin in isolation.
Multiple RCTs and meta-analyses support a link between lutein/zeaxanthin supplementation and slowed cognitive decline in older adults. An fMRI-based RCT (n=44, mean age 72) found that 12 mg/day L+Z for one year buffered verbal learning decline (Cohen's d=0.84) and enhanced cerebral perfusion in prefrontal regions. Epidemiological data consistently associate higher circulating zeaxanthin with better cognitive function and lower dementia incidence.
Zeaxanthin co-supplemented with lutein improves tear production, stability, and quality while reducing ocular surface inflammation in DED across multiple RCTs. An 8-week double-blind RCT (n=155) with zeaxanthin 4 mg + lutein + curcumin + vitamin D3 significantly improved Schirmer test and OSDI (p<0.001). A 20-day RCT (n=110) reduced OSDI by ~52%.
Zeaxanthin is a macular xanthophyll carotenoid that, together with lutein, comprises the macular pigment responsible for filtering blue light from digital screens. The 2025 Frontiers in Nutrition RCT (n=70, 6 months, 10 mg lutein + 2 mg zeaxanthin daily) in high-screen users demonstrated significant improvements in objective tear film and visual recovery measures vs. placebo. Zeaxanthin is the dominant isomer at the foveal center, where visual acuity is most critical.
Zeaxanthin is a xanthophyll carotenoid that, along with lutein, constitutes the macular pigment of the human eye and is selectively concentrated in the foveal region. Multiple RCTs and the AREDS2 trial support its role in reducing AMD progression and protecting against blue-light phototoxicity. Epidemiological and clinical evidence links higher serum zeaxanthin to reduced cataract and AMD risk.
Zeaxanthin, a macular xanthophyll carotenoid co-found with lutein in the retina, has antioxidant and neuroprotective effects relevant to glaucoma. It is a component of multiple evidence-based glaucoma supplement formulas studied in clinical trials. A 2018 systematic review listed zeaxanthin among nutrients with putative glaucoma-protective effects.
Zeaxanthin is a dietary xanthophyll co-concentrated with lutein in the macular retina with synergistic protection against age-related macular degeneration (AMD). The AREDS2 RCT (n=4,203) confirmed lutein+zeaxanthin reduces AMD progression by 26%. Zeaxanthin also contributes to cognitive protection in aging through its antioxidant and anti-inflammatory properties.
Zeaxanthin, alongside lutein, is one of only two carotenoids concentrated in the human lens and retinal macula. A meta-analysis found that high zeaxanthin blood levels are associated with a 37% lower risk of nuclear cataracts. Zeaxanthin is a core component of the evidence-backed AREDS2 formula for AMD management.
Epidemiological studies and large cross-sectional analyses consistently link higher serum lutein/zeaxanthin levels with lower risks of coronary heart disease, stroke, and cardiovascular mortality, particularly in hypertensive adults. However, the AREDS2 randomized clinical trial found no significant reduction in hard cardiovascular endpoints (heart attack, stroke, CV death) from lutein+zeaxanthin supplementation in an older population. Current evidence is therefore strongest at the observational level.
Zeaxanthin is a primary macular pigment carotenoid selectively concentrated in the fovea, where it protects photoreceptors by filtering blue light and quenching singlet oxygen. AREDS2 tested lutein/zeaxanthin in over 4,000 AMD patients and found the combination superior to beta-carotene for reducing progression risk. Epidemiological studies consistently report inverse associations between serum zeaxanthin levels and AMD prevalence. Typical clinical dose is 2–10 mg/day.
Zeaxanthin is a macular xanthophyll that concentrates in the central retina, forming part of the macular pigment that protects rods and cones from oxidative stress. Higher macular zeaxanthin levels are associated with improved dark adaptation and better dim-light visual performance. Goji berry (one of the richest dietary sources) has been shown to increase macular zeaxanthin levels in a clinical trial.
Clinical trials have demonstrated that zeaxanthin-containing oral supplements reduce wrinkle count and improve skin hydration compared to placebo. Zeaxanthin accumulates in skin tissue and is believed to decrease UV-induced ROS formation that drives photoaging. A published PubMed RCT of a zeaxanthin-based dietary supplement showed superior hydration and reduced wrinkle count versus placebo in female subjects.
Clinical trials and in vitro studies indicate that zeaxanthin (alongside lutein) improves measurable skin elasticity parameters and upregulates hyaluronic acid biosynthesis in keratinocytes. The Palombo 2007 DBPC trial found topical zeaxanthin/lutein was most effective at improving skin elasticity. In vitro work in human keratinocyte models showed xanthophyll treatment significantly induced hyaluronic acid synthesis, a key determinant of skin structural integrity.
Zeaxanthin, a carotenoid structural isomer of lutein, has demonstrated photoprotective properties. Oral high-dose zeaxanthin has been shown to protect against sunburn, cause a skin tint resembling a tan, and allow sunburned skin to recover more healthily. It is commonly studied alongside lutein in photoprotective carotenoid combination trials.
Body systems that Zeaxanthin may help support.
Go back